Company: NCEL
Filing Date: 2025-01-28
Form Type: 425
Source: 0001213900-25-007315
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-01-28
Form: 425
Chunk 1
---
, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:-----------------------|:-----------------------|:--------------------|:------------------------|
|                        |                        | Name:               | Alexander Zwyer         |
|                        |                        | Title:              | Chief Executive Officer |

<div align='center'>2</div>

Exhibit 99.1

<div align='center'>NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence</div>

| ● | Centers for Disease Control and Prevention (the “CDC”) reported                   
 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl |

| ● | Mazindol ER potentially offers a non-opioid alternative, addressing the 
 underlying neurochemical imbalances associated with fentanyl addiction. |

| ● | Mazindol ER is patent protected beyond September 2038 |

Zurich, Switzerland - January 28, 2025 – NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company
dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical
program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global
health crisis and was recently declared a national public health emergency by the new Trump administration. In 2023, the CDC reported
105,007 drug overdose deaths with 90% involving synthetic opioids like fentanyl.

“The opioid epidemic, and specifically the rise of fentanyl dependence,
presents an urgent medical need for innovative, non-opioid treatment approaches,” said Alex Zwyer, Chief Executive Officer of NLS.
“We are committed to exploring the unique pharmacological profile of Mazindol, which targets multiple neurotransmitter systems implicated
in opioid addiction. This preclinical program represents an important step in developing a potentially transformative therapy.”

Highlights of the Preclinical Program
Mazindol, a tetracyclic compound with a distinct pharmacological profile, has shown potential in mitigating opioid dependence by acting
on multiple neurotransmitter pathways, including:

| ● | 5-HT1A receptor modulation: Regulates mood, anxiety, and reward pathways, 
 addressing psychological aspects of opioid withdrawal.